Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, developed by Shanghai Junshi Biosciences. In the specific clinical trial context at Shanghai Pulmonary Hospital, it is being investigated as a neoadjuvant therapy in combination with histology-specific chemotherapy for the treatment of locally advanced (Stage III-IVA) thymic epithelial tumors. The chemotherapy component typically consists of cisplatin, doxorubicin (adriamycin), and cyclophosphamide (CAP regimen) for thymoma patients, or carboplatin and paclitaxel for thymic carcinoma patients. This combination approach aims to enhance anti-tumor immune responses by blocking PD-1/PD-L1 interactions while providing direct cytotoxic effects to downstage tumors prior to radical surgical resection.
- Brand names
- Tuoyi
- Other names
- Toripalimab plus chemotherapyToripalimab + CAPToripalimab + Carboplatin + Paclitaxelneoadjuvant Toripalimab plus chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + chemotherapy.